Genpharmasec Q1 Results: Standalone profit rises to ₹157 lakh
Genpharmasec Limited reported a standalone net profit of ₹156.96 lakh for Q1FY26, rising slightly from ₹155.92 lakh in Q1FY25. Consolidated results showed a net loss of ₹17.37 lakh due to losses in non-controlling interests. Revenue from operations grew significantly to ₹4,478.44 lakh on a standalone basis. The Pharmaceuticals segment remained the primary profit driver, while Manufacturing & Processing and Laboratory Testing segments incurred losses.
*this image is generated using AI for illustrative purposes only.
Genpharmasec Limited reported a standalone net profit of ₹156.96 lakh for the quarter ended June 30, 2026, marking a slight increase from ₹155.92 lakh in the corresponding period of FY25. The Board of Directors approved the unaudited financial results at a meeting held on August 11, 2026, in Mumbai. While the standalone entity remained profitable, the group’s consolidated position turned negative, reporting a net loss of ₹17.37 lakh for the quarter, primarily driven by losses attributable to non-controlling interests.
The filing was made pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subsequently approved by the Board. Bilimoria Mehta & Co., Chartered Accountants, served as the independent auditors, issuing an unmodified review report. The audit committee reviewed the financial statements on August 11, 2026, before they were tabled before the Board.
Financial Performance Overview
On a standalone basis, revenue from operations rose significantly to ₹4,478.44 lakh in Q1FY26, up from ₹1,211.32 lakh in Q1FY25. Total income reached ₹4,575.50 lakh, supported by other income of ₹97.06 lakh. Expenses totaled ₹4,365.78 lakh, with purchase of stock-in-trade accounting for ₹4,530.97 lakh, partially offset by a decrease in inventories of ₹249.05 lakh. Profit before tax stood at ₹209.72 lakh, against a tax expense of ₹52.76 lakh.
| Metric | Q1FY26 (₹ Lakh) | Q1FY25 (₹ Lakh) |
|---|---|---|
| Revenue from Operations | 4,478.44 | 1,211.32 |
| Total Income | 4,575.50 | 1,293.55 |
| Total Expenses | 4,365.78 | 1,122.97 |
| Profit Before Tax | 209.72 | 170.58 |
| Net Profit | 156.96 | 155.92 |
Consolidated revenue from operations was ₹4,971.03 lakh, compared to ₹1,204.32 lakh in the previous year’s quarter. However, total expenses were higher at ₹4,982.57 lakh, leading to a profit before tax of only ₹25.77 lakh. After a total tax expense of ₹43.13 lakh, the group reported a net loss of ₹17.37 lakh. This contrasts with a consolidated net profit of ₹121.52 lakh in Q1FY25.
Segment-wise Analysis
The Pharmaceuticals segment contributed ₹4,478.44 lakh to revenue and generated a segment result (profit before tax and interest) of ₹222.41 lakh. The Manufacturing & Processing segment reported revenue of ₹271.92 lakh but incurred a segment loss of ₹125.07 lakh. The Laboratory Testing segment posted a loss of ₹29.20 lakh with no reported revenue for the quarter. Unallocable items accounted for ₹220.67 lakh in revenue and a minor loss of ₹2.45 lakh.
Total segment assets increased to ₹15,628.35 lakh from ₹13,815.34 lakh in the preceding quarter. Segment liabilities rose to ₹9,064.44 lakh from ₹7,250.86 lakh. The Pharmaceuticals segment held the largest share of assets at ₹6,918.07 lakh and liabilities at ₹3,936.34 lakh.
What the Numbers Show
A divergence exists between the standalone profitability and the consolidated loss position. While the parent company reported a stable net profit, the consolidated loss of ₹17.37 lakh was largely driven by non-controlling interests, which attributed a loss of ₹43.34 lakh to the group. This suggests that subsidiaries or joint ventures may be facing operational challenges that are not reflected in the parent company’s direct operations. Additionally, the Laboratory Testing and Manufacturing & Processing segments continued to report losses, indicating ongoing pressure in these business lines despite strong performance in Pharmaceuticals.
Historical Stock Returns for Genpharmasec
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.90% | 0.0% | -8.04% | -16.94% | -48.50% | -81.20% |
What specific operational challenges are driving the losses in the Manufacturing & Processing and Laboratory Testing segments, and does management have a turnaround strategy for these units?
How will the significant increase in segment liabilities, particularly within the Pharmaceuticals division, impact the company's debt-to-equity ratio and future borrowing costs?
Given the consolidated loss attributed to non-controlling interests, are there plans to restructure subsidiaries or joint ventures to mitigate these drag factors on group profitability?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
